Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy

BACKGROUND: Rolapitant, a novel neurokinin‐1 receptor antagonist, provided effective protection against chemotherapy‐induced nausea and vomiting (CINV) in a randomized, double‐blind phase 3 trial of patients receiving moderately emetogenic chemotherapy or an anthracycline and cyclophosphamide regime...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Hesketh, Paul J., Schnadig, Ian D., Schwartzberg, Lee S., Modiano, Manuel R., Jordan, Karin, Arora, Sujata, Powers, Dan, Aapro, Matti
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084806/
https://ncbi.nlm.nih.gov/pubmed/27176138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados